# Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination

> **NCT02684799** · PHASE1 · COMPLETED · sponsor: **Tobira Therapeutics, Inc.** · enrollment: 48 (actual)

## Conditions studied

- Healthy

## Interventions

- **DRUG:** Cenicriviroc
- **DRUG:** Omeprazole
- **DRUG:** Famotidine

## Key facts

- **NCT ID:** NCT02684799
- **Lead sponsor:** Tobira Therapeutics, Inc.
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2016-01-31
- **Primary completion:** 2016-04-11
- **Final completion:** 2016-04-11
- **Target enrollment:** 48 (ACTUAL)
- **Last updated:** 2017-11-24


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT02684799

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT02684799, "Pharmacokinetic and Safety Study of Cenicriviroc and Acid Reducing Agents When Dosed Alone or in Combination". Retrieved via AI Analytics 2026-07-13 from https://api.ai-analytics.org/clinical/NCT02684799. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*